4 research outputs found
SARS-CoV-2 reinfection in patients negative for immunoglobulin G following recovery from COVID-19
While many patients infected by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) eventually produce neutralising antibodies, the degree of susceptibility of previously infected individuals to reinfection by SARS-CoV-2 is currently unknown. To better understand the impact of the immunoglobulin (IgG) level on reinfection in recovered coronavirus disease 2019 (COVID-19) patients, anti-nucleocapsid IgG levels against SARS-CoV-2 were measured in 829 patients with a previously confirmed infection just after their recovery. Notably, 87 of these patients had no detectable IgG concentration. While there was just one case of asymptomatic reinfection 4.5 months after the initial recovery amongst patients with detectable anti-nucleocapsid IgG levels, 25 of the 87 patients negative for anti-nucleocapsid IgG were reinfected within one to three months after their first infection. Therefore, patients who recover from COVID-19 with no detectable anti-nucleocapsid IgG concentration appear to remain more susceptible to reinfection by SARS-CoV-2, with no apparent immunity. Also, although our results suggest the chance is lower, the possibility for recovered patients with positive anti-nucleocapsid IgG findings to be reinfected similarly exists
OXA-carbapenemases present in clinical acinetobacter baumannii-calcoaceticus complex isolates from patients in kurdistan region, Iraq
In addition to intrinsic resistance in Acinetobacter baumannii, many different types of acquired resistance mechanisms have been reported, including the presence of VIM and IMP metallo β-lactamases and also of blaOXA-23-like and blaOXA-58-like enzymes. In the Kurdistan region of Iraq, the multiresistant A. baumannii-calcoaceticus complex is prevalent. We characterized the different mechanisms of resistance present in clinical isolates collected from different wards and different hospitals from the Kurdistan region. One hundred twenty clinical nonduplicate A. baumannii-calcoaceticus complex isolates were collected from four hospitals between January 2012 and October 2013. The identification of the isolates was confirmed by MALDI-TOF.
The sus